-
平臺(tái)編號(hào)：bio-68883
-
國(guó)際編號(hào)：CRL-2683?
-
細(xì)胞信息： TSHR-R5T-34
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
TSHR-R5T-34
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：IgG1; kappa light chain
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
ATCC Number：CRL-2683?
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
規(guī)格：0.5mg Designations: TSHR-R5T-34
Depositors: ?H Loosfelt, E Milgrom
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human thyroid stimulating hormone (TSH) receptor beta subunit, extracellular domain
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with recombinant human thyroid stimulating hormone (TSH) receptor expressed in. E. coli.
Spleen cells were fused with Sp2/0 mouse myeloma cells.
The antibody recognizes the N-terminal extracellular domain (amino acids domain 357-389), beta subunit of the human thyroid stimulating hormone (TSH) receptor. It recognizes an extracellular epitope of the beta subunit anchored into the cellular membrane.
The antibody does not interfere with hormone binding and has no effect on the receptor mediated adenylate cyclase activity.
The antibody cross-reacts with rodent TSH receptor.
The TSHR-R5T-34 (ATCC CRL-2683 ) antibody recognizes a N-terminal extracellular epitope of the beta subunit while the TSHR-T3-365 (ATCC CRL-2684 ) antibody recognizes a C-terminal intracellular subunit of the beta subunit.
The antibodies can be used in Western Blot, ELISA, immunocytochemistry, and immunohistochemistry assays of the human TSH receptor.
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 90%; heat-inactivated horse serum, 10%
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: Culture medium, 45%; heat-inactivated horse serum, 45%; DMSO, 10%.
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
References: 56151: Baratti-Elbaz C, et al. Internalization and recycling pathways of the thyrotropin receptor. Mol. Endocrinol. 13: 1751-1765, 1999. PubMed: 10517676
56155: de Bernard S, et al. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain. J. Biol. Chem. 274: 101-107, 1999. PubMed: 9867816
免疫類(lèi)型：IgG1; kappa light chain
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
ATCC Number：CRL-2683?
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
規(guī)格：0.5mg Designations: TSHR-R5T-34
Depositors: ?H Loosfelt, E Milgrom
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human thyroid stimulating hormone (TSH) receptor beta subunit, extracellular domain
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with recombinant human thyroid stimulating hormone (TSH) receptor expressed in. E. coli.
Spleen cells were fused with Sp2/0 mouse myeloma cells.
The antibody recognizes the N-terminal extracellular domain (amino acids domain 357-389), beta subunit of the human thyroid stimulating hormone (TSH) receptor. It recognizes an extracellular epitope of the beta subunit anchored into the cellular membrane.
The antibody does not interfere with hormone binding and has no effect on the receptor mediated adenylate cyclase activity.
The antibody cross-reacts with rodent TSH receptor.
The TSHR-R5T-34 (ATCC CRL-2683 ) antibody recognizes a N-terminal extracellular epitope of the beta subunit while the TSHR-T3-365 (ATCC CRL-2684 ) antibody recognizes a C-terminal intracellular subunit of the beta subunit.
The antibodies can be used in Western Blot, ELISA, immunocytochemistry, and immunohistochemistry assays of the human TSH receptor.
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 90%; heat-inactivated horse serum, 10%
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: Culture medium, 45%; heat-inactivated horse serum, 45%; DMSO, 10%.
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
References: 56151: Baratti-Elbaz C, et al. Internalization and recycling pathways of the thyrotropin receptor. Mol. Endocrinol. 13: 1751-1765, 1999. PubMed: 10517676
56155: de Bernard S, et al. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain. J. Biol. Chem. 274: 101-107, 1999. PubMed: 9867816
